DCGI Approves ENTOD Pharmaceuticals' PresVu Eye Drops, Enabling Spectacle-Free Reading For Presbyopia Patients
Entod Pharmaceuticals Limited is recognized as one of the leading players in the Indian Pharmaceuticals industry, recently granted Final Approval by the Drug Controller General of India for its Novel Presbyopia medicine pres뷰 eye drops, marking a quantum leap in the management of presbyopia. This recommendation at CDSCO follows the approval by the SEC, considering the potential of the product to reduce the dependence on reading glasses in people affected with this common age-related vision condition. PresVu is an innovative product; it is the first eye drop in India, meant for dealing with presbyopia, which normally affects people above 40 years of age. The formulation and process of PresVu are also pending patent approval, flagging the innovativeness.
Besides improving near vision, PresVu has the additional advantage of lubricating the eyes, thus adding comfort to the user. These eye drops make use of an advanced dynamic buffer technology that quickly adjusts to tear pH levels to ensure continued safety and efficacy for extended use, meeting the need for a long-term solution. Presbyopia is the natural result of aging, ranging from 1.09 billion to 1.80 billion people around the world, thereby affecting domestic productivity and the quality of life.
